Excited to announce that our paper is officially out! Check it out if you’re interested in adding RSV to your labs sequencing repertoire!
Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B https://t.co/RNQbOw1cej
Today marks the start of the RSV vaccination programme in England, Wales and Northern Ireland.
This is a welcome move to help reduce the adverse health impacts associated with RSV infection in infants. Find our more our website: https://t.co/vWsarswVVF
Many are unaware of the respiratory illness #RSV, but it causes 20,000 hospitalisations each year in babies under 1, just in England.
Find out about the new vaccination programme launching this autumn to help thousands of children & older adults: https://t.co/xiZHJPt8Dv 1/2
How do we study viruses? What is a vaccine? And why don’t viruses kill us all? 🦠
👩💻 A new online @coursera series led and developed by @imperialcollege's infectious disease experts will explore all you need to know about #viruses and #vaccines.💉👇
I would urge any healthcare professional in the UK to sign this letter to the UK Government, urging them to introduce RSV immunisation this coming winter
https://t.co/BpVxndpysH
Countries across Europe have already introduced nirsevimab, a long-acting RSV monoclonal antibody 1/2
#ESWISummit 🔛 #RSV#NIRSEGAL
🎙️@fedemartinon
▶️ Successful implementation in Galicia by high coverage & high impact
▶️89% decrease in hospitalisations in infants below 6 months
▶️#Nirsevimab could prevent up to 128.196 medical interventions due to RSV annually in Spain
The first three months of nirsevimab in Galicia show a significant impact on RSV hospitalization rates. Last full report at https://t.co/DQXFGhkUMj or https://t.co/y52ieeSrRu #nirsegal
Just published! The first paper ever! on the real world implementation of nirsevimab as universal prophylaxis against RSV. Data from Galicia (Spain) showing its implementation plan and first coverage results https://t.co/KDeEqlKYPE @Eurosurveillanc#NIRSEGAL@Xunta@SanidadeXunta
First Published @PROMISE_IMI 'European RSV Surveillance Bulletin Reporting Week 40/2023'!
Based on surveillance data from 6 countries, RSV activity are at low levels in Europe, w/ only sporadic activity reported in France & the Netherlands.
👉https://t.co/DaZjdyrcIf